Yusho
Conditions
Interventions
For the symptoms of numbness and sensation deterioration in Yusho patients, pregabalin 25 mg is orally administered for 4 weeks and the effect judgment is carried out and the result is analyzed. In ad
Sponsors
Nagasaki University Hospital Dermatology / Allergy Department
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who satisfy all the following criteria are targeted. 1.Age: patients aged 50 or older at the time of acquisition 2.Gender: No prejudice 3.Hospitalization / Outpatient: Outpatient only 4.After receiving sufficient explanation for participation in this study, patients who obtained document consent by the patient's free will with sufficient understanding. 5.Patient who is untreated for abnormal sensation of limbs or patient who is inadequate in current symptomatic treatment.
Exclusion criteria
Exclusion criteria: Patients applicable to even one of the following are excluded as subjects. 1.Patient currently taking pregabalin 2.Patients with serious liver and kidney dysfunction 3.Patients with drug hypersensitivity such as allergy to pregabalin 4.In addition, patients whose research managers judged inappropriate as research subjects
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The effect of pregabalin on sensory disorders such as numbness of the subjects is compared for each of VAS, Von frey, and heat sensation for each difference before pregabalin administration and at the end of administration (4th week after administration start). | — |
Countries
Japan
Contacts
Public ContactYoshiyuki Kamio
Nagasaki University Hospital Dermatology / Allergy Department
Outcome results
None listed